|
Acta Pharmacologica Sinica 2005 February; 26 (2): 129-142; doi: 10.1111/j.1745-7254.2005.00020.x |
| Review | [
Full text ] |
| Development of novel therapies for Huntington's disease: hope and challenge1 |
Zheng-hong QIN2,3,5, Jin WANG4, Zhen-lun GU2 2Department of Pharmacology, Soochow University School of Medicine, Suzhou 215007, China; 3Laboratory of Cellular Neurobiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA; 4Molecular Neurogenetics Unit, Center for Human Genetics Research, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA |
Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5-10 out of 10 000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HD, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology. |
Keywords: Huntington disease; huntingtin; aggregates; caspases; nerve growth factors; cell trans-plantation; coenzyme Q10 |
| 1 Supported by the National Natural Science Foundation of China (No 30370506). |
| 5 Correspondence to Zheng-hong QIN, PhD. Phn 86-512-6512-2087. Fax 86-512-6519-0599. E-mail zhqin5@hotmail.com Received 2004-11-04 Accepted 2004-12-07 |
[
Full text ] |
Copyright©APS 2009 Add: 294 Tai-Yuan Road, Shanghai 200031, China Phn: 86-21-5492-2821 Fax: 86-21-5492-2823 E-mail: aps@mail.shcnc.ac.cn |